🔴 Corcept Therapeutics is trading 4.7% down today on profit-taking after post-earnings surge

Corcept Therapeutics is trading at approximately $112.79, down 4.7% as the stock consolidates following a massive rally in the previous session.

• Shares spiked more than 27% on July 30 after the company reported Q2 2026 results that crushed analyst estimates and prompted management to raise full-year revenue guidance.
• The positive outlook is driven by robust Lifyorli oncology sales and continued growth in the company’s Cushing’s syndrome franchise.
• Analysts view today's decline as normal profit-taking and consolidation following the outsized move rather than a shift in underlying fundamentals.